All News

23 April 2025

Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDASmall Molecules

23 April 2025

Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi’s Intention to Make a Strategic Investment in the CompanyAntibodies

23 April 2025

Ensem Therapeutics Announces U.S. FDA IND Clearance to Initiate Clinical Development of ETX-636Small Molecules

23 April 2025

Tagworks Pharmaceuticals Announces FDA Clearance of IND Application and Initiation of Phase 1 Clinical Trial for TGW101 and Appoints Keith Orford, MD, PhD, as Chief Medical OfficerAntibodies

23 April 2025

Onward Therapeutics Announces IMPD Approval for Its Subsidiary Emercell to Start Clinical Investigation of Allogeneic NK Cell Therapy OT-C001 in Combination with RituximabDNA RNA and Cells

23 April 2025

Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational AntibodyAntibodies

23 April 2025

Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 DegraderSmall Molecules

23 April 2025

AP Biosciences Doses First Patient in Phase 1/2 Clinical Trials of AP402 for HER2+ Cancer PatientsAntibodies

21 April 2025

Acepodia Presents Preclinical Data on Antibody-Dual-Drugs Conjugation (AD2C) technology at AACR Annual Meeting 2025Antibodies

21 April 2025

K-679: A Novel Antibody Drug-loaded Unimicelle Conjugate with Ultra-High Drug Loading Capacity Demonstrates Superior Efficacy in EGFR-Expressing Solid TumorsAntibodies

21 April 2025

Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast CancerAntibodies

21 April 2025

Ono Commences Research Collaboration with Jorna Therapeutics to Generate Novel RNA Editing TherapeuticsMore News

21 April 2025

Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)Proteins and Peptides

21 April 2025

ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast CancerAntibodies

19 April 2025

Akeso’s Ebdarokimab ( IL – 12/IL – 23 Dual – Targeted Monoclonal Antibody) Approved in China for Moderate – to – Severe Plaque PsoriasisAntibodies

19 April 2025

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticariaAntibodies

18 April 2025

Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple myelomaAntibodies

18 April 2025

VelaVigo Announces Second Out-Licensing Deal, of a First-in-Class Bi-specific Antibody, Further Validating Its Innovative Discovery Platform and Sustainable BD+VC Business ModelAntibodies

18 April 2025

Magnet-Like Nanoparticle Vaccine Achieves 100% Protection Against H5N1 in Preclinical TrialsVaccines

18 April 2025

Endevica Bio Announces First Patient Dosing in Phase 2 Trial in Patients with Stage 4 Metastatic Colorectal CancerProteins and Peptides

17 April 2025

Lilly’s oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trialSmall Molecules

17 April 2025

Earendil Labs Announces Worldwide Exclusive License Agreement with Sanofi for Next-Generation Bispecific Antibodies for Autoimmune and Inflammatory Bowel DiseasesAntibodies

17 April 2025

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 – a Novel IRAK4 Degrader for Inflammatory ConditionsSmall Molecules

17 April 2025

Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid TumorsDNA RNA and Cells

17 April 2025

BigHat Biosciences and Lilly Collaborate to Advance AI-Driven Antibody TherapeuticsMore News

17 April 2025

Henlius’ Innovative Anti-HER2 mAb HLX22 in Combination with T-Dxd Advances to a Phase 2 Clinical Trial for the Treatment of HER2-low, HR-positive BC with First Patient DosedAntibodies

17 April 2025

Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149Small Molecules

16 April 2025

Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid ArthritisAntibodies

16 April 2025

Sabin Begins Marburg Vaccine Trial in U.S.Vaccines

16 April 2025

Radiance Announces First Patient Dosing in Phase 1 Clinical Trial of its Next Generation ROR-1 Targeted ADC for Hematologic and Solid MalignanciesAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

2023 Sales of Antibodies & Proteins

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

PD-1 x VEGF and PD-L1 x VEGF bispecific antibodies: a business, pipeline and competitor analysis from an industry perspective

2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA

Bispecific Antibodies for Immuno-Oncology & Other Diseases

TL1A Inhibitor Pipeline Review

Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

CD73 Inhibitor Pipeline Review

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective